Treatment with an anti-CK2 synthetic peptide improves clinical response in COVID-19 patients with pneumonia. A randomized and controlled clinical trial
LR Cruz, I Baladrón, A Rittoles, PA Díaz… - ACS pharmacology & …, 2020 - ACS Publications
The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein
kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been …
kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been …
<? covid19?> High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2
E Smith, ME Davis-Gardner… - … the Science of Drug …, 2020 - journals.sagepub.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late
2019 has triggered an ongoing global pandemic whereby infection may result in a lethal …
2019 has triggered an ongoing global pandemic whereby infection may result in a lethal …
Targeting inflammation and cytokine storm in COVID-19
Q Huang, X Wu, X Zheng, S Luo, S Xu… - Pharmacological Research, 2020 - Elsevier
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million …
S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2
JDA Tyndall - Journal of Medicinal Chemistry, 2022 - ACS Publications
The coronavirus disease (COVID-19) pandemic has highlighted the ability of scientists to
quickly react to the immense challenge presented to the world. The orally available 3CL …
quickly react to the immense challenge presented to the world. The orally available 3CL …
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
WC Chiou, MS Hsu, YT Chen, JM Yang… - Journal of enzyme …, 2021 - Taylor & Francis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for
coronavirus disease 2019 (COVID-19). Since its emergence, the COVID-19 pandemic has …
coronavirus disease 2019 (COVID-19). Since its emergence, the COVID-19 pandemic has …
Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
J Kladnik, A Dolinar, J Kljun, D Perea… - Journal of enzyme …, 2022 - Taylor & Francis
Abstract Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione
complex 2a, were synthesised and evaluated for the stability in biologically relevant media …
complex 2a, were synthesised and evaluated for the stability in biologically relevant media …
[HTML][HTML] Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury
M Oz, DE Lorke - Biomedicine & Pharmacotherapy, 2021 - Elsevier
The recent emergence of coronavirus disease-2019 (COVID-19) as a pandemic affecting
millions of individuals has raised great concern throughout the world, and the severe acute …
millions of individuals has raised great concern throughout the world, and the severe acute …
Neutrophil Elastase inhibitor (Sivelestat), may be a promising therapeutic option for Management of Acute Lung Injury/acute respiratory distress syndrome or …
A Sahebnasagh, F Saghafi, M Safdari… - Authorea …, 2020 - advance.sagepub.com
This article summarizes the effects of sivelestat on ALI/ARDS or ARDS with coagulopathy,
both of which are frequently seen in patients with COVID-19. The emergence of the novel …
both of which are frequently seen in patients with COVID-19. The emergence of the novel …
Cathepsin G and neutrophil elastase contribute to lung-protective immunity against mycobacterial infections in mice
K Steinwede, R Maus, J Bohling… - The Journal of …, 2012 - journals.aai.org
The neutrophil serine proteases cathepsin G (CG) and neutrophil elastase (NE) are involved
in immune-regulatory processes and exert antibacterial activity against various pathogens …
in immune-regulatory processes and exert antibacterial activity against various pathogens …
[HTML][HTML] In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate
S Di Micco, S Musella, MC Scala, M Sala… - Frontiers in …, 2021 - frontiersin.org
The most severe outcome of COVID-19 infection is the development of interstitial pneumonia
causing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), both …
causing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), both …